How CRISPR gene editing might soon protect us against Alzheimer's

The challenge: There is evidence that Alzheimer's may be developing in the brain as much as <u>30 years</u> before symptoms appear, but there isn't a way to easily and accurately diagnose it that early.

Follow the latest news and policy debates on sustainable agriculture, biomedicine, and other 'disruptive' innovations. Subscribe to our newsletter.

SIGN UP

In 2012, researchers studying the genes of people in Iceland discovered a rare mutation in the [amyloid precursor protein, or] APP gene that makes it harder for the enzyme to break apart the precursor protein.

As a result, people with the mutation have "strong protection" against Alzheimer's, as well as general cognitive decline and memory loss.

People with this mutation are "five times more likely to reach 85 without being diagnosed with Alzheimer's," according to <u>Nature</u>, and "also live longer, with a 50% better chance of celebrating their 85th birthday."

Researchers at Canada's University of Laval have now <u>used a CRISPR technique</u> known as "prime editing" to successfully insert the Icelandic mutation into up to 68.9% of human cells treated in the lab.

. . .

Looking ahead: For the <u>CRISPR</u> treatment to be effective, it would need to edit the genes in a significant portion of the brain's cells, and CRISPR faces the same issue as other treatments in <u>crossing the bloodbrain barrier</u>.

This is an excerpt. Read the original post here.